Valuation: Gilead Sciences, Inc.

Market Cap 167B 146B 135B 124B 234B 16,077B 238B 1,615B 633B 7,866B 626B 612B 27,101B P/E 2026 *
-48.4x
P/E 2027 * 17x
Enterprise Value 176B 154B 143B 131B 248B 16,989B 252B 1,707B 669B 8,313B 662B 647B 28,639B EV / Sales 2026 *
5.78x
EV / Sales 2027 * 5.15x
Free-Float
99.88%
Yield 2026 *
2.42%
Yield 2027 * 2.5%
1 day-0.71%
1 week+1.69%
Current month+5.76%
1 month+7.00%
3 months-1.66%
6 months+7.63%
Current year+8.86%
1 week 129.4
Extreme 129.405
140.61
1 month 123
Extreme 123
140.61
Current year 116.88
Extreme 116.88
157.29
1 year 107.75
Extreme 107.75
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Sell

Chief Financial Officer

-3,000 0.0002%
7/15/26 Sell

Executive/Senior Manager

-3,000 0.0002%
7/1/26 Sell

Chief Executive Officer

-15,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-0.36%+1.69%+23.40%+67.14% 167B
-1.74%-1.59%+52.60%+150.76% 1,051B
-1.44%-3.05%+52.04%+48.41% 609B
-8.31%+2.11%+36.99%+78.09% 450B
-0.75%+0.30%+29.77%+21.15% 330B
-1.52%-1.19%+34.46%+35.35% 284B
-1.70%-1.82%+20.99%+15.74% 263B
-0.58%+1.11%-20.18%-40.59% 223B
+0.15%+1.34%+23.46%+56.62% 198B
-1.20%+1.45%+2.37%-32.46% 143B
Average -0.96%+0.23%+25.59%+40.02% 371.78B
Weighted average by Cap. -1.14%-0.50%+35.81%+68.04%

Financials

2026 *2027 *
Net sales 30.47B 26.71B 24.69B 22.7B 42.84B 2,938B 43.52B 295B 116B 1,438B 114B 112B 4,953B 32.4B 28.4B 26.25B 24.14B 45.55B 3,124B 46.28B 314B 123B 1,529B 122B 119B 5,267B
Net income -3.39B -2.97B -2.75B -2.53B -4.77B -327B -4.84B -32.85B -12.88B -160B -12.73B -12.46B -551B 9.76B 8.56B 7.91B 7.27B 13.72B 941B 13.94B 94.57B 37.07B 461B 36.66B 35.86B 1,587B
Net Debt 9.46B 8.29B 7.66B 7.05B 13.3B 912B 13.51B 91.65B 35.93B 446B 35.52B 34.75B 1,538B -
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-20 $133.21 -0.80% 4,085,769
26-07-17 $134.28 -1.48% 6,903,235
26-07-16 $136.30 +3.49% 7,926,819
26-07-15 $131.70 +1.28% 4,467,637
26-07-14 $130.04 -1.04% 5,255,960
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
134.28USD
Average target price
158.30USD
Spread / Average Target
+17.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock